Commentary: Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1–3a follicular lymphoma

• by Guilan Cheng, Kewei Yang, Dan He, Yue Liu, Hongmiao Li, Liangying Zhang, Qingxian Jia, Yuanping Yin, Zhihan Zhao

• August 26, 2026

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

• by Luca Paruzzo, Emeline R. Chong, Elise A. Chong, Zhixuan Zheng, Puneeth Guruprasad, Daniel J. Landsburg, Sunita D. Nasta, Federico Stella, Ranjani Ramasubramanian, Vitor B. de Souza, Mohannad H. Alkhatib, Matthew Ho, Antonio Imparato, Gregory M. Chen, Don L. Siegel, Gabriela Plesa, Anlan Dai, Shane Mackey, Priyamvada Das, Peter Michener, Julie Jadlowsky, Frederic D. Bushman, Vrutti Patel, Alberto Carturan, Ellen B. Napier, Vanessa E. Gonzalez, Danuta Jarocha, Rong Xu, Bruce L. Levine, Patrizia Porazzi, Noelle Frey, David L. Porter, Jakub Svoboda, Joseph A. Fraietta, Carl H. June, Stephen J. Schuster, Marco Ruella

• August 26, 2026

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose

• by Yueying Chen, Fulin Nian, Shengdi Wu, Tianli Yuan, Yifan Ma, Junyang Cao, Yuxiao Zhang, Wenfeng Liu, Wenqing Tang, Danying Zhang, Zi Li, Wei Lu, Fengwanni Wang, Xiulong Xia, Zhanju Liu, Si Zhang, Xizhong Shen, Xiaoming Hu, Ling Dong

• August 25, 2026

Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

• by

• August 26, 2026

• 3 min